1[1]Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase Ⅲ trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [C]. Program and abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology;June 5-8, 2004; New Orleans, Louisiana. Abstract 7010.
2[2]Herbst RS, Prager D, Hermann R, et al. TRIBUTE:a phase Ⅲ trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) [C]. Program and abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology;June 5-8,2004; New Orleans, Louisiana. Abstract 7011.
3[3]Shepherd FA, PereiraJ, CiuleanuTE, etal. Arandomized placebo-controlled trial or erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy [C]. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Program and abstracts of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, Louisiana.Abstract 7022.
4[4]Giaccone G, Johnson DH, Manegold C, et al. A phase Ⅲ clinical trial of ZD1839( ‘Iressa' ) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non small-cell lung cancer (INTACT 1) [abstract no. 4] [J]. Ann Oncol, 2002, 13:2.
5[5]Johnson DH, Herbst R, Giaccone G, et al. ZD1839 ("Iressa")in combination with paclitaxel and carboplatin in chemotherapy naive patients with advanced non-small-cell lung cancer (NSCLC): resukse Ⅲ clinical trial (INTACT 2) [abstract no.468] [J]. Ann Oncol, 2002, 13:127.
6[6]Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J]. J Clin Oncol, 2003, 22(12): 2237-2246.
7[7]Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine, in symptomatic patients with non-small cell lung cancer [J ]. JAMA,2003, 290(16) :2149-2158.
8[8]Coiffier B. Related ArRituximab in combination with CHOP improves survival in elderly patients with aggressive non Hodgkin's lymphoma [J]. Semin Oncol, 2002, 29(2 Suppl 6):18-22.
9[9]Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [J]. N Engl J Med, 2001,344:783-792.
10[10]Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents [J]. Drugs, 2000, 60(suppl 1):25-32.
